Int. Journal of Clinical Pharmacology and Therapeutics, Volume 40 - September (422 - 423)

A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil
A. Boshier1, N. Pambakian2, S.A.W. Shakir1
1 Drug Safety Research Unit, Southampton, and 2 General Practitioner, London, UK

Add to Cart  

 

DOI 10.5414/CPP40422

Abstract

Sildenafil is a phosphodiesterase-type-5 inhibitor indicated for the treatment of erectile dysfunction in men. We report a case of NAION identified from a cohort of 8,893 patients (from a Prescription-Event Monitoring study) prescribed sildenafil by their primary care physician in England between April and June 1999. This 61-year-old patient had risk factors for NAION independent of drug therapy. It was not possible to be confident about a causal association between sildenafil and NAION, though the possibility could not be ruled out. Epidemiological data suggest that one case of NAION might be expected in a cohort of 8,893 subjects. Thus it remains important for clinicians to consider the range of risk factors for NAION; while equally, the processes of pharmacovigilance need to continue as for any recently launched drug preparation.

Author Details

Authors

Departments

  • 1 Drug Safety Research Unit, Southampton, and
  • 2 General Practitioner, London, UK

Address

Dr. A. Boshier; Clinical Research Fellow Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton SO31 1AA, UK

Log in for Subscribers

Citation

A. Boshier, N. Pambakian and S.A.W. Shakir. A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil. 2002; 40: 422-423. doi: 10.5414/CPP40422.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart